Suppr超能文献

膜转运蛋白:中枢神经系统药物研发面临的一项挑战。

Membrane transporter proteins: a challenge for CNS drug development.

作者信息

Girardin François

机构信息

Unit of Clinical Psychopharmacology, Geneva University Hospitals, Chênes-Bourg, Geneva, Switzerland.

出版信息

Dialogues Clin Neurosci. 2006;8(3):311-21. doi: 10.31887/DCNS.2006.8.3/fgirardin.

Abstract

Drug transporters are membrane proteins present in various tissues such as the lymphocytes, intestine, liver, kidney, testis, placenta, and central nervous system. These transporters play a significant role in drug absorption and distribution to organic systems, particularly if the organs are protected by blood-organ barriers, such as the blood-brain barrier or the maternal-fetal barrier. In contrast to neurotransmitters and receptor-coupled transporters or other modes of interneuronal transmission, drug transporters are not directly involved in specific neuronal functions, but provide global protection to the central nervous system. The lack of capillary fenestration, the low pinocytic activity and the tight junctions between brain capillary and choroid plexus endothelial cells represent further gatekeepers limiting the entrance of endogenous and exogenous compounds into the central nervous system. Drug transport is a result of the concerted action of efflux and influx pumps (transporters) located both in the basolateral and apical membranes of brain capillary and choroid plexus endothelial cells. By regulating efflux and influx of endogenous or exogenous substances, the blood-brain barrier and, to a lesser extent the blood-cerebrospinal barrier in the ventricles, represents the main interface between the central nervous system and the blood, i.e., the rest of the body. As drug distribution to organs is dependent on the affinity of a substrate for a specific transport system, membrane transporter proteins are increasingly recognized as a key determinant of drug disposition. Many drug transporters are members of the adenosine triphosphate (ATP)-binding cassette (ABC) transporter superfamily or the solute-linked carrier (SLC) class. The multidrug resistance protein MDR1 (ABCB1), also called P-glycoprotein, the multidrug resistance-associated proteins MRP1 (ABCC1) and MRP2 (ABCC2), and the breast cancer-resistance protein BCRP (ABCG2) are ATP-dependent efflux transporters expressed in the blood-brain barrier They belong to the superfamily of ABC transporters, which export drugs from the intracellular to the extracellular milieu. Members of the SLC class of solute carriers include, for example, organic ion transporting peptides, organic cation transporters, and organic ion transporters. They are ATP-independent polypeptides principally expressed at the basolateral membrane of brain capillary and choroid plexus endothelial cells that also mediate drug transport through central nervous system barriers.

摘要

药物转运体是存在于多种组织中的膜蛋白,如淋巴细胞、肠道、肝脏、肾脏、睾丸、胎盘和中枢神经系统。这些转运体在药物吸收以及向机体各系统的分布中发挥着重要作用,尤其是当这些器官受到血-器官屏障保护时,如血脑屏障或母胎屏障。与神经递质、受体偶联转运体或其他神经元间传递方式不同,药物转运体并不直接参与特定的神经元功能,而是为中枢神经系统提供整体保护。脑毛细血管缺乏窗孔、吞饮活性低以及脑毛细血管与脉络丛内皮细胞之间的紧密连接,进一步构成了限制内源性和外源性化合物进入中枢神经系统的屏障。药物转运是位于脑毛细血管和脉络丛内皮细胞基底外侧膜和顶端膜上的外排泵和内流泵(转运体)协同作用的结果。通过调节内源性或外源性物质的外排和内流,血脑屏障以及在较小程度上脑室中的血脑脊液屏障,代表了中枢神经系统与血液即身体其他部分之间的主要界面。由于药物向各器官的分布取决于底物对特定转运系统的亲和力,膜转运蛋白越来越被认为是药物处置的关键决定因素。许多药物转运体是三磷酸腺苷(ATP)结合盒(ABC)转运体超家族或溶质载体(SLC)家族的成员。多药耐药蛋白MDR1(ABCB1),也称为P-糖蛋白,多药耐药相关蛋白MRP1(ABCC1)和MRP2(ABCC2),以及乳腺癌耐药蛋白BCRP(ABCG2)是在血脑屏障中表达的ATP依赖性外排转运体。它们属于ABC转运体超家族,可将药物从细胞内转运到细胞外环境。溶质载体SLC家族的成员包括,例如,有机离子转运肽、有机阳离子转运体和有机离子转运体。它们是主要在脑毛细血管和脉络丛内皮细胞基底外侧膜表达的非ATP依赖性多肽,也介导药物通过中枢神经系统屏障的转运。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4bd/3181821/d0f8ef78d9bd/DialoguesClinNeurosci-8-311-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验